摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

isoxazolo[5,4-b]pyridine-3,4,6-triamine | 253170-23-9

中文名称
——
中文别名
——
英文名称
isoxazolo[5,4-b]pyridine-3,4,6-triamine
英文别名
[1,2]Oxazolo[5,4-b]pyridine-3,4,6-triamine
isoxazolo[5,4-b]pyridine-3,4,6-triamine化学式
CAS
253170-23-9
化学式
C6H7N5O
mdl
——
分子量
165.154
InChiKey
JPJPVCOBHFKWTE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    117
  • 氢给体数:
    3
  • 氢受体数:
    6

反应信息

  • 作为反应物:
    描述:
    isoxazolo[5,4-b]pyridine-3,4,6-triamine 在 palladium on activated charcoal 氢气 作用下, 以 甲醇 为溶剂, 反应 24.0h, 以93%的产率得到4,6-diamino-2-pyridone-3-carboxamidine
    参考文献:
    名称:
    The G−C DNA Base Hybrid:  Synthesis, Self-Organization and Structural Analysis
    摘要:
    The guanine-cytosine base hybrid 1 is synthesized in five steps from the malononitrile dimer. One face of the molecule possesses the cytosine AAD hydrogen bonding code and the other the guanine DDA code. The expression of this information leads to the self-organization of six molecules of 1 into a hexagonal supermacrocycle in the solid state through the formation of 18 strong hydrogen bonds. This is the first structurally characterized example of a synthetic hexagonal assembly where the molecular program is unambiguous and all of the information required for exclusive rosette formation is contained within hydrogen bonding codes. 1 crystallizes in the very rare, high-symmetry cubic space group , with 96 molecules in the unit cell. The crystal is highly solvated and only ca. 35% occupied by molecules of 1, with a criss-crossed network of channel voids generated by the overlapping of 1(6) hexamers.
    DOI:
    10.1021/jo990719t
  • 作为产物:
    参考文献:
    名称:
    The G−C DNA Base Hybrid:  Synthesis, Self-Organization and Structural Analysis
    摘要:
    The guanine-cytosine base hybrid 1 is synthesized in five steps from the malononitrile dimer. One face of the molecule possesses the cytosine AAD hydrogen bonding code and the other the guanine DDA code. The expression of this information leads to the self-organization of six molecules of 1 into a hexagonal supermacrocycle in the solid state through the formation of 18 strong hydrogen bonds. This is the first structurally characterized example of a synthetic hexagonal assembly where the molecular program is unambiguous and all of the information required for exclusive rosette formation is contained within hydrogen bonding codes. 1 crystallizes in the very rare, high-symmetry cubic space group , with 96 molecules in the unit cell. The crystal is highly solvated and only ca. 35% occupied by molecules of 1, with a criss-crossed network of channel voids generated by the overlapping of 1(6) hexamers.
    DOI:
    10.1021/jo990719t
点击查看最新优质反应信息

文献信息

  • HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS
    申请人:eFFECTOR Therapeutics, Inc.
    公开号:US20170145009A1
    公开(公告)日:2017-05-25
    The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula IA or Formula IB, as well as stereoisomers, tautomers or pharmaceutically acceptable salts thereof. For Formula IA and Formula IB compounds A 1 , A 2 , A 3 , A 4 , W 1 , W 2 , Y, X, R 1 , R 2 , R 3 , R 4a , R 4b , R 5a , R 5b , R 6 , R 7 , R 8 , R 9 , R 9a , R 9b , R 10 and subscript n are as defined in the specification. The inventive Formula IA and Formula IB compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
查看更多

同类化合物

苯胺,4-肼基-3-甲氧基-N-苯基- 环丁[b][1,2]恶唑并[4,5-e]吡啶 异恶唑并[5,4-B]吡啶-3-胺 异噁唑并[5,4-c]吡啶-3-胺 异噁唑并[5,4-b]吡啶-3-醇 异噁唑并[4,5-b]吡啶-3-胺 异噁唑并[4,5-b]吡啶-3(2H)-酮 [1,2]恶唑并[5,4-e]吲嗪 9-氧杂-3-氮杂三环[5.2.1.03,8]癸-1,5,7-三烯 7H-[1,3]恶唑并[3,2-a]环氧乙烷并[d]吡啶 7-羟基-3-甲基[1,2]恶唑并[4,5-b]吡啶-5(4H)-酮 6-甲氧基-3-甲基[1,2]恶唑并[4,5-c]吡啶 6-(叔丁基)-3-甲基异噁唑并[5,4-B]吡啶-4-羧酸 5-肼基-3-甲基[1,2]恶唑并[4,5-b]吡啶 5-乙基-3-甲基[1,2]恶唑并[5,4-b]吡啶 5-乙基-3-甲基[1,2]恶唑并[4,5-b]吡啶 5,7-二氯-3-甲基异噁唑并[4,5-B]吡啶 4-甲氧基-3-甲基[1,2]恶唑并[5,4-b]吡啶 4-氧杂-7-氮杂三环[4.3.1.03,7]癸-1(9),2,5-三烯 4,6-二甲基异噁唑(5,4-B)吡啶-3-胺 3-甲基异噁唑并[5,4-b]吡啶 3-甲基[1,2]恶唑并[5,4-b]吡啶-5-甲酰氯 3-甲基[1,2]恶唑并[4,5-b]吡啶2-氧化物 3-甲基-6-噻吩-2-基异恶唑并[5,4-b]吡啶-4-羧酸 3-甲基-5H-异恶唑并[4,5-c]吡啶-4-酮 3-溴异噁唑并[5,4-B]吡啶 3-氨基异恶唑[4,5-C]并吡啶 3-(溴甲基)异噁唑并[5,4-B]吡啶 3-(1,3-苯并二恶唑-5-基)-N-[(1S)-1-苯乙基]-异唑并[5,4-c]吡啶-5-胺 3,6-二甲基[1,2]恶唑并[5,4-b]吡啶-4-醇 3,6-二甲基[1,2]恶唑并[5,4-b]吡啶 3,4-二甲基[1,2]恶唑并[5,4-b]吡啶-6(7H)-酮 2H-环戊二烯并[d]异噻唑并[5,4-b]吡啶(9CI) 2H-环戊二烯并[b][1,2]恶唑并[4,5-e]吡啶 2H-[1,2]恶唑并[5,4-b]吡咯并[3,4-D]吡啶 2-氯-N-异噁唑并[5,4-B]吡啶-3-基乙酰胺 1H-咪唑,1-丁基-2,5-二氢-2-(1-甲基乙基)- Methyl 3-cyclohexyloxy-6-cyclopropyl-[1,2]oxazolo[5,4-b]pyridine-4-carboxylate Prop-2-ynyl 6-cyclopropyl-3-methyl-[1,2]oxazolo[5,4-b]pyridine-4-carboxylate (S)-ethyl 2-(2-((3,5-dimethylisoxazol-4-yl)(hydroxy)methyl)furo[3,2-b]pyridin-5-yl)acetate (6-Chloropyridin-3-yl)methyl 6-cyclopropyl-3-methyl-[1,2]oxazolo[5,4-b]pyridine-4-carboxylate 5-Furyl-7-methyl-furo<2,3-c>pyridin 3-methyl-6,7,8,9-tetrahydro-5H-cyclohepta[b]isoxazolo[4,5-e]pyridine 6-bromoisoxazolo[4,5-b]pyridin-3-amine 7-((S)-2-hydroxy-1-methyl-ethylamino)-[1,6]naphthyridine-2-carboxylic acid [(S)-(3-fluoro-phenyl)-(1-methyl-1H-pyrazol-4-yl)-methyl]-amide 7-bromo-3-(4-chloro-phenyl)-4-hydroxy-isoxazolo[5,4-c]pyridine-5-carboxylic acid ethyl ester 3-(4-methoxy-phenyl)-4-hydroxy-isoxazolo[5,4-c]pyridine-5-carboxylic acid ethyl ester 6-Cyclopropyl-3-methoxy-[1,2]oxazolo[5,4-b]pyridine-4-carboxylic acid Methanone, (3-amino-1-piperidinyl)[6-(2,5-dimethyl-3-thienyl)-3-methylisoxazolo[5,4-b]pyridin-4-yl]- 9-(4-Chloro-phenyl)-3-(3,4-dichloro-phenyl)-5-methyl-isoxazolo[4,5-e][1,2,4]triazolo[4,3-c]pyrimidine